Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

Chemistry World January 20, 2010 Phil Taylor	Screw tightens on pay-for-delay drug deals Scrutiny of the tactics used by pharmaceutical companies to delay the entry of generics onto the market is rising on both sides of the Atlantic amid claims that the practice is costing consumers billions every year.
Chemistry World November 28, 2008 Matt Wilkinson	EU claims pharma delaying tactics cost 3 billion euros Pharmaceutical manufacturers have been criticised by the EU competition commission for slowing the entry of generic medicines to the market.
Chemistry World July 10, 2009 Sarah Houlton	Branded drugs' competition-free days numbered Authorities in the US and Europe are to look carefully at the tactics pharmaceutical firms use to delay competition from generic versions of their branded drugs.
Managed Care September 2006	Payers, Consumers Benefit as Patents Expire The generic drug market seems ready to explode, according to reports from IMS Health and the Generic Pharmaceuticals Association.
The Motley Fool January 25, 2010 Brian Orelli	Pay-for-Delay Is Under the Spotlight It helps each side, but governments aren't thrilled with the idea.
Chemistry World October 4, 2013 Phillip Broadwith	Lundbeck cuts jobs in Europe, but expands in US Danish drugmaker Lundbeck is cutting 180-200 jobs in Europe as part of its ongoing restructuring program. However, the company is currently in the process of expanding its staff in the US.
The Motley Fool April 25, 2006 Brian Gorman	Pharma Plays With Fire Drugmakers' short-term gain could lead to long-term pain.
The Motley Fool June 25, 2009 Brian Orelli	Loss of a Settlement Option Earlier this month the Federal Trade Commission came out with a report arguing for limited patent protection for drugs made by biotech companies. Now it's ratcheting up its complaints about pharmaceutical and generic-drug companies as well.
The Motley Fool March 15, 2007 Brian Lawler	It's All Good for Drugmakers With the whole drug industry growing so strongly, those looking for a safe place to park their investing dollars would be smart to take a look at some of the largest generic drugmakers.
Pharmaceutical Executive September 1, 2012 Jill Wechsler	Costs, Coverage, and Court Decisions Its election season and drug pricing issues are once again front and center in the policy wars on managing the high cost of healthcare.
Chemistry World June 17, 2012 Andrew Turley	Lundbeck to lose 600 jobs The Danish company says it must cut jobs 'to mitigate increased pressure from healthcare reforms, generic competition and uncertainty regarding pricing and reimbursement in Europe'.
Managed Care May 2004	Biologics Among Fastest Growers Managed care plans and pharmacy benefit managers can benefit from the strong generic presence in the market, but also face challenges relating to biotech drugs.
Chemistry World April 19, 2013 Phillip Broadwith	Objections raised to GSK pay-for-delay deals The UK Office of Fair Trading has said that GlaxoSmithKline's deals to delay generic drugs infringed competition laws.
The Motley Fool July 9, 2010 Brian Orelli	Changing Pay-For-Delay Will Hurt Everyone Whether you're an investor in brand-name drugs or in companies that make generics, FTC chairman Jon Leibowitz is not your friend.
Chemistry World January 21, 2015 Ned Stafford	euro 2.7bn research cuts to fund Europe's stimulus package unveiled The European commission has revealed which research programs will be cut to fund its stimulus package.
Chemistry World January 6, 2014 Sarah Houlton	Weathering the storm Pharma is in the middle of a strategic crisis, if a report published at the start of 2013 by Roland Berger Strategy Consultants is to be believed.
Pharmaceutical Executive April 1, 2014	Whatever Happened To Faster Reimbursement For Generics In Europe? The plan to accelerate generic pricing and reimbursement has become another tragic European casualty.
Pharmaceutical Executive October 1, 2005 Glass & Worrell	Whose Afraid of Authorized Generics Losing a patent challenge lets a generic competitor grab market share and slash branded profits. Sound scary? Ignoring authorized generics is worse.
The Motley Fool January 31, 2007 Brian Lawler	Mylan on the Generic Attack Two new drug approvals for the generic drugmaker come in the midst of a changing regulatory environment. Investors, take note.
The Motley Fool January 30, 2007 Brian Lawler	Par Passes the Generic Bar Par Pharmaceutical Companies gets approval to market another generic product, but the company still has to complete the restatement of its past financials. Investors, take note.
The Motley Fool November 27, 2006 Brian Lawler	Teva and Pfizer Make Up The companies decide to play nice over generic versions of two of Pfizer's drugs.
Chemistry World June 1, 2015 Ned Stafford	Scientists hail partial victory on efforts to block cuts to European research programme All-night negotiations between European politicians led to the protection of key areas of the EU's research program.
The Motley Fool May 21, 2009 Brian Orelli	If You Can't Beat 'Em, Join 'Em: Pharma Goes Generic In the battle against generic rivals, it seems pharmaceutical companies would rather switch than fight. A pair of deals heralds Big Pharma's latest moves into the generic-drug world. See what Novartis and sanofi-aventis recently did.
The Motley Fool February 15, 2011 Brian Orelli	Obama Hates Your Drugmaker The president's proposal in favor of earlier generics would mean lower profits for some companies.
Managed Care November 2006	The Formulary Files Step therapy for antidepressants saves 11.7 percent in one year.
The Motley Fool June 22, 2006 Stephen D. Simpson	Merck Goes on the Attack Predator becomes prey in this latest twist in the generics game. Given how much the markets hate uncertainty, that could mean that big generic drug companies might go on sale for patient long-term investors.
Chemistry World July 15, 2014 Emma Stoye	Public--private research partnerships to tackle Europe's big problems The European Union will invest euro 7.3 billion in seven newly launched public -- private partnerships as part of its Horizon2020 research funding program.
Chemistry World July 2, 2014 Emma Stoye	Graphene Flagship doubles in size The Graphene Flagship aims to take graphene 'from the lab to the factory floor' over the next 10 years, with a large investment from the European commission.
The Motley Fool December 30, 2008 Brian Orelli	2009's Generic Drugs: Who's at Risk The patent cliff is coming early for some drugmakers.
Chemistry World September 6, 2013 Dinsa Sachan	Another drug suspension overturned in India An Indian high court has quashed the suspension of a popular antidepressant. This comes shortly after the suspension of the diabetes drug pioglitazone was overturned.
The Motley Fool October 16, 2006 Brian Lawler	The Coming Generic Drug Boom Generic drugmakers are poised to profit from several key factors. Investors, take note.
Chemistry World March 25, 2010 Rebecca Trager	Big pharma scores in US healthcare reform President Obama has signed the biggest US healthcare reform since the 1960s, and although it is largely seen as a victory for the pharmaceutical industry, some analysts are characterising it as a 'double-edged sword'.